Adicet Bio (ACET) director receives stock options for 4,200 shares at $8.10

Rhea-AI Filing Summary

Adicet Bio director Michael Grissinger received a new stock option award covering 4,200 shares of Common Stock. The option was granted at an exercise price of $8.10 per share and expires on June 20, 2036. Following this grant, he holds options for 4,200 shares directly.

The award vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board. This is a compensation-related grant, not an open‑market purchase or sale.

Insights

Equity compensation analyst

Routine director stock option grant with standard vesting terms.

Director Michael Grissinger was granted options on 4,200 shares of Adicet Bio Common Stock at an exercise price of $8.10 per share, expiring in 2036. This is classified as a grant or award acquisition, not a market trade.

The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on continued board service. With 4,200 options outstanding after the transaction and no sales reported, this appears to be routine equity compensation rather than a signal about the company’s near‑term prospects.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grissinger Michael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 4,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 4,200 shares Exercise price: $8.10 per share Expiration date: June 20, 2036 +1 more

4 metrics

Option grant size 4,200 shares Stock Option (Right to Buy) underlying Common Stock

Exercise price $8.10 per share Stock option strike price

Expiration date June 20, 2036 Option expiration

Post-transaction options held 4,200 shares Total options following transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-20T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"These shares shall vest in full on the earlier to occur"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

board of directors financial

"subject to the Reporting Person's continued service on the Issuer's board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grissinger Michael

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/21/2026		A		4,200		(1)	06/20/2036	Common Stock	4,200	$0	4,200	D

Explanation of Responses:

1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adicet Bio (ACET) director Michael Grissinger report on this Form 4?

He reported receiving a stock option grant for 4,200 shares of Adicet Bio Common Stock. The option is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a preset exercise price in the future.

What are the key terms of Michael Grissinger’s new Adicet Bio (ACET) stock options?

The grant covers 4,200 shares of Common Stock at an exercise price of $8.10 per share and expires on June 20, 2036. These terms define how many shares he can buy, at what price, and until when the option remains exercisable.

How and when do Michael Grissinger’s Adicet Bio (ACET) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditional on his continued service on Adicet Bio’s board of directors through that vesting date, according to the footnote.

Did Michael Grissinger buy or sell Adicet Bio (ACET) shares in the market?

No market purchases or sales were reported. The Form 4 shows a grant of stock options classified as a grant or award acquisition. This type of transaction reflects equity compensation, not an open-market decision to buy or sell existing shares.

How many Adicet Bio (ACET) options does Michael Grissinger hold after this transaction?

Following the reported transaction, he holds options for 4,200 underlying shares of Adicet Bio Common Stock directly. This figure reflects his position after the new grant and helps show the scale of his derivative equity-based compensation from the company.